AMENDMENTS TO THE CLAIMS

This listing of claims will replace all previously submitted listings of claims in this application:

1.-275. **(Cancelled)**

276. **(Previously presented)** A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising: contacting a multi-epitopic antigen selected from the group consisting of CA125, CA19.9, CA15.3 and PSA present in a host's serum with a composition comprising a non-radiolabeled antibody or antigen binding fragment thereof that specifically binds to a first epitope on the multi-epitopic *in vivo* antigen, whereby the antibody or antigen binding fragment thereof forms an immune complex with the antigen, and whereby an effective host T cell response is elicited against the antigen in the immune complex.

277. **(Previously presented)** A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising: contacting a multi-epitopic antigen selected from the group consisting of CA125, CA19.9, CA15.3 and PSA present in a host's serum with a composition comprising a non-radiolabeled antibody or antigen binding fragment thereof that specifically binds to an epitope on the multi-epitopic *in vivo* antigen, whereby the antibody or antigen binding fragment thereof forms an immune complex with the antigen, and whereby the complex elicits an effective host humoral immune response against a second epitope of the multi-epitopic *in vivo* antigen.

278. **(Previously presented)** A method for inducing a therapeutic host immune response against a multi-epitopic *in vivo* antigen that does not elicit an effective host immune response, the method comprising: contacting a multi-epitopic antigen selected from the group consisting of CA125, CA19.9, CA15.3 and PSA present in a host's serum with a composition comprising a non-radiolabeled antibody or antigen binding fragment thereof that specifically binds to an

epitope on the multi-epitopic *in vivo* antigen, whereby the antibody or antigen binding fragment thereof forms an immune complex with the antigen, and whereby the complex elicits an effective host T cell response against the antigen in the immune complex and an effective humoral immune response against a second epitope of the multi-epitopic *in vivo* antigen.

279. **(New)** The method of claim 276, wherein the antigen is CA125.

280. **(New)** The method of claim 279, wherein the antigen CA125 is present in the host's serum at levels greater than 100 U/ml.

281. **(New)** The method of claim 279, wherein the host has ovarian cancer.

282. **(New)** The method of claim 279, wherein the antibody is B43.13 which is producible by a hybridoma having ATCC deposit number PTA-1883, or an antigen binding fragment of said antibody.

283. **(New)** The method of claim 276, wherein the antigen is CA19.9.

284. **(New)** The method of claim 283, wherein the host has gastrointestinal cancer.

285. **(New)** The method of claim 283, wherein the host suffers from inflammation.

286. **(New)** The method of claim 283, wherein the antibody is Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, or an antigen binding fragment of said antibody.

287. **(New)** The method of claim 283, wherein the antibody is Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2691, or an antigen binding fragment of said antibody.

288. **(New)** The method of claim 276, wherein the antigen is CA15.3.

289. (**New**) The method of claim 288, wherein the host has breast cancer.

290. (**New**) The method of claim 276, wherein the antigen is PSA.

291. (**New**) The method of claim 290, wherein the host has prostate cancer.

292. (**New**) The method of claim 290, wherein the antibody is AR47.47 which is producible by a hybridoma having ATCC deposit number HB-12526, or an antigen binding fragment of said antibody.

293. (**New**) The method of claim 276, wherein the antibody or antigen binding fragment thereof is present in the composition in an amount of from 0.1 μg to 200 μg per kg of body weight of the host.

294. (**New**) The method of claim 276, wherein the antibody or antigen binding fragment thereof is formulated for administration to the host at a dose of about 2 mg per host.

295. (**New**) The method according to claim 276, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of a chimeric monoclonal antibody, a genetically engineered antibody, a Fab fragment, a $F(ab')_2$ fragment, a single chain antibody, and a single chain antibody fragment.

296. (**New**) The method of claim 276, wherein the composition comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

297. (**New**) The method of claim 276, wherein contacting comprises administering by intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

298. (**New**) The method of claim 276, wherein contacting comprises administering the composition in solution, tablet, or aerosol form.

299. (**New**) The method of claim 277, wherein the antigen is CA125.

300. (**New**) The method of claim 299, wherein the antigen CA125 is present in the host's serum at levels greater than 100 U/ml.

301. (**New**) The method of claim 299, wherein the host has ovarian cancer.

302. (**New**) The method of claim 299, wherein the antibody is B43.13 which is producible by a hybridoma having ATCC deposit number PTA-1883, or an antigen binding fragment of said antibody.

303. (**New**) The method of claim 277, wherein the antigen is CA19.9.

304. (**New**) The method of claim 303, wherein the host has gastrointestinal cancer.

305. (**New**) The method of claim 303, wherein the host suffers from inflammation.

306. (**New**) The method of claim 303, wherein the antibody is Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, or an antigen binding fragment of said antibody.

307. (**New**) The method of claim 303, wherein the antibody is Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2691, or an antigen binding fragment of said antibody.

308. (**New**) The method of claim 277, wherein the antigen is CA15.3.

309. (**New**) The method of claim 308, wherein the host has breast cancer.

310. (**New**) The method of claim 277, wherein the antigen is PSA.

311. (**New**) The method of claim 310, wherein the host has prostate cancer.

312. (New) The method of claim 310, wherein the antibody is AR47.47 which is producible by a hybridoma having ATCC deposit number HB-12526, or an antigen binding fragment of said antibody.

313. (New) The method of claim 277, wherein the antibody or antigen binding fragment thereof is present in the composition in an amount of from 0.1 μg to 200 μg per kg of body weight of the host.

314. (New) The method of claim 277, wherein the antibody or antigen binding fragment thereof is formulated for administration to the host at a dose of about 2 mg per host.

315. (New) The method according to claim 277, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of a chimeric monoclonal antibody, a genetically engineered antibody, a Fab fragment, a $F(ab')_2$ fragment, a single chain antibody, and a single chain antibody fragment.

316. (New) The method of claim 277, wherein the composition comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

317. (New) The method of claim 277, wherein contacting comprises administering by intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

318. (New) The method of claim 277, wherein contacting comprises administering the composition in solution, tablet, or aerosol form.

319. (New) The method of claim 278, wherein the antigen is CA125.

320. (New) The method of claim 319, wherein the antigen CA125 is present in the host's serum at levels greater than 100 U/ml.

321. (New) The method of claim 319, wherein the host has ovarian cancer.

322. (New) The method of claim 317, wherein the antibody is B43.13 which is producible by a hybridoma having ATCC deposit number PTA-1883, or an antigen binding fragment of said antibody.

323. (New) The method of claim 278, wherein the antigen is CA19.9.

324. (New) The method of claim 323, wherein the host has gastrointestinal cancer.

325. (New) The method of claim 323, wherein the host suffers from inflammation.

326. (New) The method of claim 323, wherein the antibody is Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, or an antigen binding fragment of said antibody.

327. (New) The method of claim 323, wherein the antibody is Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2691, or an antigen binding fragment of said antibody.

328. (New) The method of claim 278, wherein the antigen is CA15.3.

329. (New) The method of claim 328, wherein the host has breast cancer.

330. (New) The method of claim 278, wherein the antigen is PSA.

331. (New) The method of claim 330, wherein the host has prostate cancer.

332. (New) The method of claim 330, wherein the antibody is AR47.47 which is producible by a hybridoma having ATCC deposit number HB-12526, or an antigen binding fragment of said antibody.

333. (New) The method of claim 278, wherein the antibody or antigen binding fragment thereof is present in the composition in an amount of from 0.1 μg to 200 μg per kg of body weight of the host.

334. **(New)** The method of claim 278, wherein the antibody or antigen binding fragment thereof is formulated for administration to the host at a dose of about 2 mg per host.

335. **(New)** The method according to claim 278, wherein the antibody or antigen binding fragment thereof is selected from the group consisting of a chimeric monoclonal antibody, a genetically engineered antibody, a Fab fragment, a $F(ab')_2$ fragment, a single chain antibody, and a single chain antibody fragment.

336. **(New)** The method of claim 278, wherein the composition comprises one or more adjuvants, one or more carriers, one or more excipients, one or more stabilizers, one or more pharmaceutically acceptable carriers and/or physiologically acceptable saline.

337. **(New)** The method of claim 278, wherein contacting comprises administering by intravenous, subcutaneous, intraperitoneal, intradermal, intramuscular, or intralymphatic routes.

338. **(New)** The method of claim 278, wherein contacting comprises administering the composition in solution, tablet, or aerosol form.